EMEA-000236-PIP04-14

Key facts

Invented name
Eylea
Active substance
aflibercept
Therapeutic area
Ophthalmology
Decision number
P/0165/2014
PIP number
EMEA-000236-PIP04-14
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
  • Treatment of choroidal neovascularisation secondary to pathologic myopia
  • Treatment of branch retinal vein occlusion
Route(s) of administration
Solution for injection
Contact for public enquiries
Bayer Pharma AG
Germany
E-mail: pediatrics.medical-affairs-europe@bayer.com
Tel. +49 3046 815333
Fax +49 3046 895333
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating